RNS Number: 0695 A Destiny Pharma PLC 20 January 2020 Destiny Pharma plc. Brighton, United Kingdom- 20 January 2020- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance, announces the completion of the initial phase...
#DEST new guidelines are easing the way for Destiny's XF-73 product in Asia Pacific. Remember, this is all about the prevention of post surgical infection, not the treatment
RNS Number: 0602 X Destiny Pharma PLC 17 December 2019 Destiny Pharma plc. Brighton, United Kingdom- 17 December 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that target clear commercial opportunities and also address the global problem of antimicrobial resistance, notes that new...
Destiny Pharma to present at the Partnerships to Tackle the Global Challenge of AMR, UK- China AMR Workshop. Brighton, United Kingdom- 2 December 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of...
Brighton, United Kingdom- 2 December 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of antimicrobial resistance, announces the appointment of Dr. Barker held several senior roles including development...
RNS Number: 5505 T Destiny Pharma PLC 15 November 2019 Destiny Pharma plc. Destiny Pharma to present at the Inv€$ tival Showcase in partnership with Jefferies Brighton, United Kingdom- 15 November 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti- microbial drugs that address clear commercial opportunities...
RNS Number: 3690 S Destiny Pharma PLC 06 November 2019 Destiny Pharma plc. Brighton, United Kingdom- 5 November 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs that address clear commercial opportunities and also address the global problem of anti-microbial resistance, announces that...
RNS Number: 9980 P Destiny Pharma PLC 16 October 2019 Destiny Pharma plc. Positive results published from an independent XF-73 phase 1 clinical trial in a peer reviewed journal. Brighton, United Kingdom- 16 October 2019 Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear...
Destiny Pharma Plc (DEST.L) Announced, in its interim results for the six months ended 30 June 2019, that the operating loss rose to £2.47 million from £2.62 million posted in the same period preceding year. The company’s profit before tax stood at £2.43 million, compared to loss of £2.58 million reported in the previous year. The basic and diluted loss per share stood at 4.8p compared to loss per share of 5.2p reported in the previous year. The company’s cash and equivalents stood at £5.08 million. Also, it announced that after 18 years on the Board, Joe Eagle a Non-Executive Director, has decided to step down from the Board with immediate effect.
XF-73 nasal gel Phase 2 b patient recruitment underway in US and Europe, results expected mid-2020. Brighton, United Kingdom- 23 September 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs that address clear commercial opportunities and also address the global problem of anti-microbial...
RNS Number: 2027 N Destiny Pharma PLC 23 September 2019 Destiny Pharma plc. Brighton, United Kingdom- 23 September 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis caused by antimicrobial resistance, today announces that after 18 years on the Board, Joe Eagle a...
Brighton, United Kingdom- 12 September 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis caused by antimicrobial resistance, will announce its financial results for the six months ended 30 June 2019 on Monday 23 September 2019.. A presentation for analysts will...
RNS Number: 7317 L Destiny Pharma PLC 10 September 2019. Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections. Brighton, United Kingdom- 10 September 2019- Destiny Pharma plc, a clinical stage biotechnology company focused on the development of novel...
Destiny Pharma Plc (DEST.L) Announced that data from its collaboration, 'Evaluation of XF Drugs as Antibiotic Resistance Breakers', with Cardiff University is being presented at the EuroBiofilms conference, in Glasgow, 3-6 September 2019. The poster, entitled 'Evaluation of the novel XF Drugs: Potent antibacterial drugs with Twin Mechanisms of Action', is being presented by Dr Emma Board-Davies, Post-Doctoral Research Associate, School of Pharmacy and Pharmaceutical Sciences, Cardiff University. The data looks at the potency of Destiny Pharma's product platform, including XF-73, XF-70 and DPD-207, against a range of the critical, infection causing bacteria.
RNS Number: 8021 K Destiny Pharma PLC 02 September 2019. Brighton, United Kingdom- 2 September 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance, announces that data from its collaboration,' Evaluation of XF Drugs as Antibiotic...
RNS Number: 2141 J Destiny Pharma PLC 15 August 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Brighton, United Kingdom- 31 July 2019- Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance, announces that Dr Jesus Gonzalez, Chief Medical Officer of Destiny Pharma, has been invited to present on the clinical potential of the...
RNS Number: 1716 G Destiny Pharma PLC 19 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    43.69M

Company Profile

Destiny Pharma plc is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Classification

Market Indices-

Locations

HQ
Sussex Innovation Centre
Science Park Square
Falmer
Brighton
BN1 9SB
Watchlist